1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,873 | 0,897 | 13.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 53,66 | +0,22 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| GENMAB | 250,40 | -0,95 % | H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX | ||
| ARBUTUS BIOPHARMA | 3,338 | -0,60 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| VERICEL | 29,800 | -1,97 % | Vericel Corporation: Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026 | ||
| MOLECULIN BIOTECH | 4,340 | +3,58 % | Moleculin launches CEO Corner to enhance investor communication | ||
| SENSEI BIOTHERAPEUTICS | 9,280 | +2,09 % | Sensei Biotherapeutics, Inc. - 8-K, Current Report | ||
| MUSTGROW BIOLOGICS | 0,360 | 0,00 % | Bayer-Aktie auf der Überholspur! Partner MustGrow Biologics vor Neubewertung! | Für Bayer läuft es derzeit hervorragend. Das Unternehmen bekommt seine Problemfelder in den Griff und meldet Erfolge im Pharmabereich. Im Schatten davon hat man sich die Lizenz für eine neue biologisch... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,310 | -1,21 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| AKEBIA | 1,100 | +8,37 % | Akebia Therapeutics, Inc.: Akebia Announces Establishment of Rare Kidney Disease Pipeline | Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease... ► Artikel lesen | |
| REGENXBIO | 6,750 | +0,75 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| ZEVRA THERAPEUTICS | 7,100 | -0,70 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,900 | +1,47 % | B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, $16 target | ||
| CORVUS PHARMACEUTICALS | 16,240 | +3,31 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M | SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,100 | -0,97 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| NANOBIOTIX | 20,900 | +0,48 % | Nanobiotix S.A.: NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris | PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen |
Das Unternehmen SYNTHAVERSE SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,879 Euro und damit -0,79 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.